🔎 Trials Near Me

Hem › Burkitts lymfom › Oklahoma

Kliniska studier för Burkitts lymfom i Oklahoma

7 studier för Burkitts lymfom söker deltagare vid platser i Oklahoma.

Städer i Oklahoma

Officiell studietext (engelska)

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • University of Oklahoma Health Sciences Center, Oklahoma City
RekryterarFas 3
Ålder 18 till 39 · Alla kön · Uppdaterad 2 okt. 2026 · NCT03150693

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • University of Oklahoma Health Sciences Center, Oklahoma City
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 29 sep. 2026 · NCT03739814

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • University of Oklahoma Health Sciences Center, Oklahoma City
  • Saint Francis Children's Hospital, Tulsa
RekryterarFas 2
Ålder 1 till 30 · Alla kön · Uppdaterad 1 sep. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • University of Oklahoma Health Sciences Center, Oklahoma City
  • Saint Francis Children's Hospital, Tulsa
RekryterarFas 3
365 Days – 25 Years · Alla kön · Uppdaterad 25 aug. 2026 · NCT03959085

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

  • University of Oklahoma Health Sciences Center, Oklahoma City
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 31 juli 2026 · NCT07069699

Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.